Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Santa Clarita Radio13h
Stand Out To Employers: Building The Perfect Cover Letter With AI
We’ve all been there — sending out countless job applications with generic cover letters that barely get a glance from hiring ...
Ask a Manager1d
this is how to write a good cover letter
Over the course of my career, I’ve read probably tens of thousands of cover letters. (And yes, that’s as boring as it sounds.) What I’ve learned from ...
The Cut on MSN1d
How to Write a Cover Letter That Will Get You a Job
A great cover letter won’t get you the job if you’re not qualified, but it can make a hiring manager notice you in a sea of ...
Schrodinger announces expanded license agreement with Novartis
Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...
Benzinga.com14d
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...
The Pharma Letter15d
Novartis’ Scemblix gains FDA approval in newly diagnosed CML
Novartis (NOVN: VX) late yesterday revealed that Scemblix ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free ...
FiercePharma15d
Novartis' Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...
Investopedia15d
Novartis Posts Results Above Estimates, Raises Outlook
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...
STAT16d
Novartis raises profit guidance, pushes off myelofibrosis drug submission
LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...
The Pharma Letter16d
Novartis beats estimates and raises outlook
Swiss pharma giant Novartis (NOVN: VX) revealed rising sales and earnings ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news ...
BioSpace17d
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
Novartis on Monday became the latest Big Pharma player to jump into the molecular glue space. The Swiss drugmaker signed an exclusive development and commercialization agreement with Monte Rosa ...